Shots:

• The P-II EMPhASIS study involves assessing of IMU-838 in 210 patients randomized in 36 centers across 4 EU countries- 209 patients received at least one dose of IMU-838 vs PBO and 197 patients completed @24-wks. treatment period
• The study resulted in meeting its 1EPs & 2EPs: 62% & 70% reduction in CUA MRI lesions up to @24wks. in patients receiving IMU-838 (45mg & 30mg qd). Rate of treatment-emergent AEs (42.9% vs 43.5%); rate of treatment withdrawals (5.0% vs 7.2%)
• Additionally- the company has reported financial results of Q2’20 with $48.6M in cash and cash equivalents. IMU-838 is an orally available DHOD inhibitor- acts on activated T and B cells and leave other immune cells largely unaffected- allowing the immune system to stay functioning

 Ref: Immunic | Image: PRNewswire